Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

With Pfizer's stock price at a three-year low, however, it might be the perfect time to start building a position (or adding to an established one) in the drugmaker. Here's why.

The stock price of Pfizer (NYSE: PFE) has outperformed the broader indices. While the S&P500 index has seen a rise of 1% over the last month or so, PFE stock is up a solid 19%. This also compares ...

In addition, Pfizer's 1.75 price-to-book value is only beaten by Sanofi's 1.65 price/book value. Stock Info with SA For the valuation model, we need to take the acquisition of Seagen into account.

Pfizer's shares currently trade at a trailing-12-month price-to-sales (P/S) ratio of 2.37. Based on the company's guidance for 2024, the stock's forward P/S multiple is roughly 2.67 (using the ...